EBV INFECTION AFTER ALLOGENIC HSCT
Clinical trials for EBV INFECTION AFTER ALLOGENIC HSCT explained in plain language.
Never miss a new study
Get alerted when new EBV INFECTION AFTER ALLOGENIC HSCT trials appear
Sign up with your email to follow new studies for EBV INFECTION AFTER ALLOGENIC HSCT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two doses of rituximab before transplant may shield children from Epstein-Barr virus
Disease control Recruiting nowThis trial tests whether giving two doses of rituximab before a stem cell transplant can prevent Epstein-Barr virus (EBV) from reactivating in children. EBV is a common virus that can cause serious illness in children with weakened immune systems after transplant. The study compa…
Matched conditions: EBV INFECTION AFTER ALLOGENIC HSCT
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Engineered immune cells take on virus in transplant patients
Disease control Recruiting nowThis early-phase trial tests whether specially engineered immune cells (EBV-TCR-T cells) can safely control Epstein-Barr virus infections in people who have had a stem cell transplant. About 12 participants will receive one to three infusions of donor-derived cells. The main goal…
Matched conditions: EBV INFECTION AFTER ALLOGENIC HSCT
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC